The Q&A session highlighted critical considerations for transitioning to single-dose HPV vaccination, including evidence needs for NITAG decision-making, updates on ongoing trials like HANDS, and the unique immunological advantages of virus-like particle vaccines. Participants raised concerns about vaccine efficacy in older adolescents, genotype distribution differences (e.g., HPV 52 prevalence), and implications for vaccine selection. Discussions […]
Topic: Product Choice
Considerations for HPV Vaccine product choice
The WHO presentation reviewed the global status of HPV vaccine introduction, noting that 74% of countries have adopted HPV vaccination programs with increasing coverage driven by major introductions in Asia and Africa. It highlighted the 2022 recommendation for a single-dose schedule, now adopted by 58 countries, including high-income nations. Recent evidence supports the inclusion of […]